

Progress in Late-Stage Product Development¹

Bausch Pharma/Solta Medical



Salix
PHARMACEUTICALS

- **Amiselimod S1P² Modulator³** – Completed the thorough QT study which evaluated the cardiac safety profile; results were positive. Initiated Phase 2 study in Q2 2021 for mild to moderate Ulcerative Colitis (83 patients enrolled to date)
- **Rifaximin SSD (RED-C: prevention of cirrhosis complications – HE⁴)** – Phase 3 trial started in 2021. Global enrollment ongoing and preparing for regulatory meetings to register outside the U.S.
- **Study of Rifaximin ER/DER capsulated beads in a Phase 1 study for Sickle Cell Anemia** – Clinical enrollments started end of 2021; expanding globally
- **Rifaximin (SIBO⁵)** – Meeting U.S. FDA to discuss a Patient Reported Outcomes tool in 1H 2022

International

- **Expect to launch ~45 products** (out of which ~25 products are from geo-expansion) across 50 markets (vary by product) in the next 5 years



Ortho | Dermatologics

- **IDP-120 (Acne)** – Phase 3 completed and met primary endpoints; currently evaluating next steps for this program (there is no decision yet)
- **IDP-126 (Acne Combination)** – Both Phase 3 studies met primary and secondary endpoints; following the results of a comparative bridging study initiated in June 2021, expected to submit NDA in 4Q22



SOLTAMEDICAL

- **Clear + Brilliant[®] Touch laser (a next generation Clear + Brilliant[®] laser)** – U.S. launch March 2021
- **Geographic Expansion**
 - Continued market expansion into EU5 countries and broader EMEA markets
 - Latin America expansion plans expected to begin in 2023